Publication
S768I Mutation in EGFR in Patients with Lung Cancer.
Authors not recorded
J Thorac Oncol2016PMID 27211795PMC5035584stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugErlotinibcivic_curation1.00
- geneEGFRcivic_curation1.00
- variantEGFR S768Icivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27211795
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR S768I1 | ||||||||
| Erlotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Does Not Support Sensitivity Response | 2 | accepted | EID2906S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treate… (full text at CIViC) PMID 27211795 · Leventakos et al., 2016 · Open in CIViC | civic |